Therefore, we conducted a descriptive systematic literature review to evaluate the overall patient-level detection rates of the three FDA-approved PSMA-targeted radiopharmaceuticals in order to evaluate their performance in patients experiencing biochemical recurrence of prostate cancer following curative-intent treatment. The gene discussed is FOLH1; the disease is prostate carcinoma.